Alvespimycin (17-DMAG) HCl

For research use only. Not for use in humans.

目录号：S1142 别名： NSC 707545,BMS 826476 HCl,KOS 1022 中文名称：阿螺旋霉素盐酸盐

Alvespimycin (17-DMAG) HCl Chemical Structure

CAS No. 467214-21-7

Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl是一种有效的HSP90抑制剂，无细胞试验中IC50为62 nM。 Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2351.34	现货
5mg	RMB 794.94	现货
25mg	RMB 2432.56	现货
大包装

大剂量询单

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Alvespimycin (17-DMAG) HCl发表文献48篇：

Transl Oncol, 2021, 14(1):100982

PubMed: 33395748 ( click the link to review the publication )

Nat Commun, 2020, 22;11(1):1935

PubMed: 32321921 ( click the link to review the publication )

Aging Cell, 2020, e13269

PubMed: 33145977 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3335

PubMed: 33187254 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2630

PubMed: 32942617 ( click the link to review the publication )

J Mol Cell Biol, 2020, 24;12(3):216-229

PubMed: 31408169 ( click the link to review the publication )

Hum Mutat, 2020, 10.1002/humu.24147

PubMed: 33252173 ( click the link to review the publication )

Front Oncol, 2020, 10:117

PubMed: 32117764 ( click the link to review the publication )

Life Sci, 2020, 15;249:117532

PubMed: 32151689 ( click the link to review the publication )

J Bioenerg Biomembr, 2020, 15

PubMed: 32291605 ( click the link to review the publication )

Theranostics, 2020, 10(18):8415-8429

PubMed: 32724478 ( click the link to review the publication )

Yonsei Med J, 2020, 61(7):587-596

PubMed: 32608202 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3562

PubMed: 31395886 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2097-2110

PubMed: 31395684 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):2069-2082

PubMed: 30916978 ( click the link to review the publication )

Nan Fang Yi Ke Da Xue Xue Bao, 2019, 39(2):169-174

PubMed: 30890504 ( click the link to review the publication )

Hepatology, 2019, 69(2):573-586

PubMed: 29356025 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4296

PubMed: 30327466 ( click the link to review the publication )

Nat Commun, 2018, 9(1):672

PubMed: 29445180 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )

Biomed Pharmacother, 2018, 105:1026-1032

PubMed: 30021337 ( click the link to review the publication )

Nat Commun, 2017, 8(1):422

PubMed: 28871086 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28619760 ( click the link to review the publication )

Int J Biol Sci, 2017, 13(4):505-517

PubMed: 28529458 ( click the link to review the publication )
Experimental Cell Research, 2017, 353(1):46-53

PubMed: 28279658 ( click the link to review the publication )

Am J Transl Res, 2017, 9(11):4945-4953

PubMed: 29218092 ( click the link to review the publication )

Cell Death Dis, 2016, 7(6):e2290

PubMed: 27362807 ( click the link to review the publication )

Sci Rep, 2016, 6:19004

PubMed: 26743233 ( click the link to review the publication )

Sci Rep, 2016, 6:38072

PubMed: 27909289 ( click the link to review the publication )

J Biol Chem, 2016,

PubMed: 27489107 ( click the link to review the publication )

Cell Stress Chaperones, 2016, 21(2):339-48

PubMed: 26786409 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Viruses, 2016, 8(11)

PubMed: 27801778 ( click the link to review the publication )

Oncotarget, 2016, 7(1):433-45

PubMed: 26595521 ( click the link to review the publication )

Molecules, 2015, 20(1):1643-60

PubMed: 25608045 ( click the link to review the publication )

Immunopharmacol Immunotoxicol, 2015, 8:1-10

PubMed: 26642940 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12128-40

PubMed: 25900240 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

Oncotarget, 2014, 5(13):4920-8

PubMed: 24952482 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2014, 17(11):778-82

PubMed: 25404267 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Hepatology, 2013, 57(1):70-80

PubMed: 22898980 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1093-102

PubMed: 23993685 ( click the link to review the publication )

FEBS J, 2013, 10.1111/febs.12672

PubMed: 24304935 ( click the link to review the publication )

PLoS One, 2013, 8(4):e59315

PubMed: 23565147 ( click the link to review the publication )

Tumour Biol, 2013, 35(4):3229-35

PubMed: 24293393 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(7):1078-85

PubMed: 22592212 ( click the link to review the publication )

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234 ( click the link to review the publication )

产品安全说明书

HSP (HSP90)抑制剂选择性比较

生物活性

产品描述

Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl是一种有效的HSP90抑制剂，无细胞试验中IC50为62 nM。 Phase 2。

特性

17-DMAG是抗生素Geldanamycin 的合成衍生物，比现有抗生素具有较低的肝毒性，比相似衍生物17-AAG效果和有效性更强。

靶点

HSP90 ^[1]
(Cell-free assay)

62 nM

体外研究

荧光偏振（FP）为基础的竞争性结合实验中，17-DMAG作用于人类 Hsp90比 17-AAG（IC50 为 119 nM）效果高2倍，IC50为 62 nM。17-DMAG作用于过量表达Hsp90“服务蛋白” Her2的SKBR3和 SKOV3细胞,下调Her2，EC50分别为8 nM和 46 nM, 且诱导 Hsp70，EC50分别为 4 nM和 14 nM,结果产生显著的毒性，GI50分别为 29 nM 和32 nM。^[1] 17-DMAG和 Vorinostat 联用，通过显著降低cyclin D1和CDK4, 及c-Myc, c-RAF 和AKT水平，协同诱导培养的MCL细胞和原发性 MCL 细胞凋亡。^[3]17-AAG 只有效作用于慢性淋巴细胞白血病 (CLL) 细胞的IKKβ，而17-DMAG 处理，有效导致Hsp90 客户蛋白IKKα 和 IKKβ的消耗,导致 NF-κB p50/p65 DNA结合减少，NF-κB 靶基因转录降低，及caspase依赖性凋亡降低。通过靶向作用于NF-κB 家族，17-DMAG作用于CLL细胞而不是正常T细胞或NK细胞，选择性调节毒性，这种作用存在剂量和时间依赖性。^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
SKBr3	NGDuNGhEgXSxdH;4bYNqfHliYYPzZZk>			NH3KT29EgXSxdH;4bYNqfHliYXfhbY5{fCCVS1LyN{Bk\WyuczygTWM2OD1yLkCyOO69VS5?	MonaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZzNkWzOVQoRjF4MU[1N\|U1RC:jPh?=
SKBR3	M3;RWmZ2dmO2aX;uJIF{e2G7			MYnVdJJm\3WuYYTpc44hd2ZiSIPwO\|AhcW5iU1vCVlMh[2WubIOsJGVEPTB;MD6wNFTPxE1w	NGPZR2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNki1OFA3Pid-MU[4OVQxPjZ:L3G+
SKBR3	NWPKWW5uTnWwY4Tpc44h[XO\|YYm=			M2HMR2Rm\3KjZHH0bY9vKG:oIFjldlIhcW5iU1vCVlMh[2WubIOsJGVEPTB;MD6wNFjPxE1w	M1:3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OEW0NFY3Lz5zNki1OFA3PjxxYU6=
SKOV3	M3TEUWZ2dmO2aX;uJIF{e2G7			M4jvO3VxemWpdXzheIlwdiCxZjDId5A4OCCrbjDTT29XOyClZXzsd{whTUN3ME2wMlAyPM7:TT6=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjh3NEC2Okc,OTZ6NUSwOlY9N2F-
SKOV3	MkL1SpVv[3Srb36gZZN{[Xl?			NXXMNW1QTGWpcnHkZZRqd25ib3[gTIVzOiCrbjDTT29XOyClZXzsd{whTUN3ME2wMlA1Ps7:TT6=	NXTQNJZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[4OVQxPjZpPkG2PFU1ODZ4PD;hQi=>
AGS	M{nOXWZ2dmO2aX;uJIF{e2G7		NHjKdVAyPiCqcoO=	NV\Lc3czUW6qaXLpeIlwdiCxZjDITWYyKGGldHn2ZZRqd25iaX6gbJVu[W5iQVfTJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiaInwc5hq[S2rbnT1Z4VlKGy3Y3nm[ZJie2ViZYjwdoV{e2mxbjDh[pRmeiBzNjDodpMh[nlicnXwc5J1\XJiYYPzZZktKEmFNUC9NE4xOzcQvF2u	M{fnXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUizPVUxLz5zN{W4N\|k2ODxxYU6=
Hep3B	Mn7aSpVv[3Srb36gZZN{[Xl?		NX\ldGxyOTZiaILz	NILVV2NKdmirYnn0bY9vKG:oIFjJSlEh[WO2aY\heIlwdiCrbjDoeY1idiCKZYCzRkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHj5dI95cWFvaX7keYNm\CCudXPp[oVz[XOnIHX4dJJme3Orb36gZYZ1\XJiMU[gbJJ{KGK7IILldI9zfGW{IHHzd4F6NCCLQ{WwQVAvODZzzszNMi=>	NInXPGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W4N\|k2OCd-MUe1PFM6PTB:L3G+
AGS	MnLPSpVv[3Srb36gZZN{[Xl?		MnXjNlQhcHK\|	MlqwWoli[mmuaYT5JI9nKGi3bXHuJGFIWyClZXzsd{B2dmSncjDuc5Jud3irYzDjc45lcXSrb37zJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;MUdOwG0v	M4XZS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUizPVUxLz5zN{W4N\|k2ODxxYU6=
NCI-H526	M2TIPGZ2dmO2aX;uJIF{e2G7	NVracZRGOSC3TR?=	NIPyXpkzPCCqcoO=	M{DBSGJqdmSrbnegZYZncW6rdImgeI8hUFOSOUCgbY4hcHWvYX6gUmNKNUh3Mk[gZ4VtdHNiYYSgNUB2VSCjZoTldkAzPCCqcoOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeR?=	NVXQOHl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2NFM2PDBpPkG3OlA{PTRyPD;hQi=>
NCI-H526	MkfiSpVv[3Srb36gZZN{[Xl?	NWmzclRMOSC3TR?=	NVfEZnNNQTZiaILz	MXTJcohq[mm2aX;uJI9nKEiVUEmwMY1m\GmjdHXkJJBzd2yrZnXyZZRqd25ib3[gbJVu[W5iTlPJMWg2OjZiY3XscJMh[XRiMTD1UUBi\nSncjC5OkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigQ>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZyM{W0NEc,OTd4MEO1OFA9N2F-
AGS	MWrGeY5kfGmxbjDhd5NigQ>?			MVzJcohq[mm2aX;uJI9nKGi7cH;4bYEucW6mdXPl[EBJUUZzIHHjeIl3[XSrb36gbY4hcHWvYX6gRWdUKGOnbHzzJIJ6KHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVA:OC5yMEO2{txONg>?	NWS5d5ZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizOVk3OzFpPkG4N\|U6PjNzPD;hQi=>
HeLa	M4TWSWZ2dmO2aX;uJIF{e2G7			NWK3dldsUW6qaXLpeIlwdiCxZjDUUmYu[WyyaHGtbY5lfWOnZDDOSk1s[XCyYVKgZYN1cX[jdHnvckBqdiCqdX3hckBJ\UyjIHPlcIx{NCCLQ{WwQVAvOTYQvF2u	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN3OU[zNUc,OTh\|NUm2N\|E9N2F-
HeLa	MV;DfZRwfG:6aXPpeJkh[XO\|YYm=			NHHZe5ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1{LkC2{txONg>?	NVzGUJN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizOVk3OzFpPkG4N\|U6PjNzPD;hQi=>
AGS	MX3DfZRwfG:6aXPpeJkh[XO\|YYm=			MliyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRWdUKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0yPs7:TT6=	NXfCOmxmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizOVk3OzFpPkG4N\|U6PjNzPD;hQi=>
A2058	M1XhUWN6fG:2b4jpZ4l1gSCjc4PhfS=>			MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlA2QCClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEKx{txONg>?	M{jV[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUK5OFg3Lz5zOEmyPVQ5PjxxYU6=
MDA-MB-231	NH7GXXlHfW6ldHnvckBie3OjeR?=			NHy1N5ZKdmirYnn0bY9vKG:oIFjzdFkxKGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO\|ZYPz[YQh[XNiaHXyNkBl\We{YXTheIlwdixiSVO1NF0xNjByNEZOwG0v	NWO5c4N1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5Nlk1QDZpPkG4PVI6PDh4PD;hQi=>
MDA-MB-231	MX\DfZRwfG:6aXPpeJkh[XO\|YYm=			NVrJeXZ7S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEW4{txONg>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl{OUS4Okc,OTh7Mkm0PFY9N2F-
A2058	MVPGeY5kfGmxbjDhd5NigQ>?			M2L6SGlvcGmkaYTpc44hd2ZiSIPwPVAhcW5iaIXtZY4hSTJyNUigZ4VtdHNuIFXDOVA:OC5yMEe5{txONg>?	MorUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7Mkm0PFYoRjF6OUK5OFg3RC:jPh?=
MDA-MB-231	Ml3WSpVv[3Srb36gZZN{[Xl?			Mmm2TY5pcWKrdHnvckBw\iCKc4C5NEBqdiCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W\|c3XkJIF{KEGtdDDk[Ydz[WSjdHnvckwhUUN3ME2wMlAyPzcQvF2u	NH30UFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEmyPVQ5Pid-MUi5Nlk1QDZ:L3G+
A2058	NX3rS2ttTnWwY4Tpc44h[XO\|YYm=			MVvJcohq[mm2aX;uJI9nKEi\|cEmwJIlvKGi3bXHuJGEzODV6IHPlcIx{KGG\|c3Xzd4VlKGG\|IFHreEBl\We{YXTheIlwdixiSVO1NF0xNjB{NEROwG0v	M{\QdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUK5OFg3Lz5zOEmyPVQ5PjxxYU6=
HuH7	M{TtTWFvfGm4aYLhcEBie3OjeR?=		NYPmN\|N1OyCmYYnz	MnzRRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTIVx[XSrdHnzJGMhfmm{dYOg[4Vvd3S7cHWgNYIhS2:wMTDpcoZm[3SnZDDpckBpfW2jbjDIeWg4KGOnbHzzJIF{e2W\|c3XkJIF{KEeDUFTIJHJPSSCxcjCxPHMhelKQQTDs[ZZmdCCjZoTldkA{KGSjeYOgZpkheVKWLWDDVkBidmGueYPpd{whTUN3ME2wMlAxOTMQvF2u	M2q3N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUO2NVkyLz5zOEmzOlE6OTxxYU6=
HuH7	MkLJRY51cX[rcnHsJIF{e2G7		M2Tpd\|Mh\GG7cx?=	MW\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDI[ZBifGm2aYOgR{B3cXK3czDn[Y5wfHmyZTCxZkBEd25zIHnu[oVkfGWmIHnuJIh2dWGwIFj1TFch[2WubIOgZZN{\XO\|ZXSgZZMhT0GSRFigVm5CKG:{IEG4V{BzWk6DIHzleoVtKGGodHXyJFMh\GG7czDz[Yxm[3SnZDD3bZRpKDRyIH7NJGhEXi15OU[gZY5lKDhyMDDuUUBjd2OncILleolzKGK7IIHSWE1RS1JiYX7hcJl{cXNuIFXDOVA:OC5yMEOx{txONg>?	M{DtRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUO2NVkyLz5zOEmzOlE6OTxxYU6=
SKBR3	MlfOSpVv[3Srb36gZZN{[Xl?			NFnr[IZDcW6maX7nJIFn\mmwaYT5JJRwKEi\|cEmwJIlvKGi3bXHuJHNMSlJ\|IHPlcIx{NCCLQ{WwQVAvODJ2zszNMi=>	M4HrVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEG3OVYzLz5zOUCxO\|U3OjxxYU6=
Hep3B	M33EZ2Z2dmO2aX;uJIF{e2G7		MmjPN\|AhdWmwcx?=	NUDlTo9vUW6qaXLpeIlwdiCxZjDofZBwgGmjLXnu[JVk\WRiSFnGNYFteGijIIDyc5RmcW5iYXPjeY12dGG2aX;uJIlvKGi3bXHuJGhmeDOEIHPlcIx{KHS{ZXH0[YQh\m:{IEOwJI1qdnNibXXhd5Vz\WRiYX\0[ZIhOTJiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrczygTWM2OD1yLkC1O\|LPxE1w	M1fvV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEeyNlE1Lz5zOUC3NlIyPDxxYU6=
Hep3B	NWXOXWJsTnWwY4Tpc44h[XO\|YYm=		Mmr5NVYhcHK\|	MYHJcohq[mm2aX;uJI9nKGi7cH;4bYEucW6mdXPl[EBXTUeIIIDyc5RmcW5ic3XjdoV1cW:wIHnuJIh2dWGwIFjldFNDKGOnbHzzJIFnfGW{IEG2JIhzeyCkeTDFUGlUSSxiSVO1NF0xNjB5OUZOwG0v	NXTPZll6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwO\|IzOTRpPkG5NFczOjF2PD;hQi=>
HCT116	NXHKTndpS3m2b4TvfIlkcXS7IHHzd4F6		M13Sc\|czKGi{cx?=	MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|LDDJR\|UxRTBwMEW3{txONg>?	NY\2XlRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyN\|E5PjRpPkG5NlMyQDZ2PD;hQi=>
SKBR3	M4T1eWN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mm\VO\|IhcHK\|	MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT2JTOyClZXzsd{Bi\nSncjC3NkBpenNuIFnDOVA:OC5yNUlOwG0v	NFuxc249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKzNVg3PCd-MUmyN\|E5PjR:L3G+
MCF7	NFzhRVVEgXSxdH;4bYNqfHliYYPzZZk>		NGK0epI4OiCqcoO=	NIjnOXVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFczKGi{czygTWM2OD1yLkC3Ne69VS5?	NG[zVos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKzNVg3PCd-MUmyN\|E5PjR:L3G+
SKOV3	MoLaR5l1d3SxeHnjbZR6KGG\|c3H5		MYW3NkBpenN?	NF6wbpZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0:YMzDj[YxteyCjZoTldkA4OiCqcoOsJGlEPTB;MD6xNlLPxE1w	Mn;MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{M{G4OlQoRjF7MkOxPFY1RC:jPh?=
SKBR3	M1yzUGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M36y[\|czKGi{cx?=	M4\vc2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMSlJ\|IHPlcIx{KGGodHXyJFczKGi{czDpckBxemW\|ZX7j[UBw\iCQUV:xJIlvcGmkaYTvdkBlcWOxdX3hdo9tNCCLQ{WwQVAvOjQQvF2u	M{jPbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkOxPFY1Lz5zOUKzNVg3PDxxYU6=
MCF7	M1i5W2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NYTFb5hzPzJiaILz	MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCrbjDwdoV{\W6lZTDv[kBPWU9zIHnubIljcXSxcjDkbYNwfW2jcn;sMEBKSzVyPUCuPFYz\|ryPLh?=	NWTh[G01RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyN\|E5PjRpPkG5NlMyQDZ2PD;hQi=>
NCI-H596	MoDSR5l1d3SxeHnjbZR6KGG\|c3H5		NHHme2I4OiCqcoO=	MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBPWTBzLXTl[olkcWWwdDDoeY1idiCQQ1mtTFU6PiClZXzsd{Bi\nSncjC3NkBpenNuIFnDOVA:OS5zzszNMi=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ\|MUi2OEc,OTl{M{G4OlQ9N2F-
MDA468	Mnf0R5l1d3SxeHnjbZR6KGG\|c3H5		NY\Vfo9JPzJiaILz	MkToR5l1d3SxeHnjbZR6KGGpYXnud5QhVlFyMT3k[YZq[2mnboSgbJVu[W5iTVTBOFY5KGOnbHzzJIFnfGW{IEeyJIhzeyxiSVO1NF0yNjcQvF2u	M1TycVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkOxPFY1Lz5zOUKzNVg3PDxxYU6=
SKBR3	MYrDfZRwfG:6aXPpeJkh[XO\|YYm=		NXLyenF5PzJiaILz	NVPaXWY1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uEUkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHz0bZRmei2pbH:gZZN{[XluIFnDOVA:OC5yMkVOwG0v	NVzYSVRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NFU2OjhpPkG5OFA2PTJ6PD;hQi=>
A549	MV;DfZRwfG:6aXPpeJkh[XO\|YYm=		NYflNnJpPzJiaILz	M2PoRmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JINmdGy2aYTldk1odG9iYYPzZZktKEmFNUC9NE4xPjkQvF2u	NGLnblA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUSwOVUzQCd-MUm0NFU2Ojh:L3G+
SKOV3	M4fIUWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MlL3O\|IhcHK\|	Ml[5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JINmdGy2aYTldk1odG9iYYPzZZktKEmFNUC9NE4zOs7:TT6=	NEjSTWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUSwOVUzQCd-MUm0NFU2Ojh:L3G+
MCF7	NUfQNVg1S3m2b4TvfIlkcXS7IHHzd4F6		MlfEO\|IhcHK\|	MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDj[YxtfGm2ZYKt[4xwKGG\|c3H5MEBKSzVyPUCuNlPPxE1w	Ml7iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2MEW1NlgoRjF7NEC1OVI5RC:jPh?=
CCRF-CEM	M33TOmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MX23NkBpenN?	MnL4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2NTTi2FRV2gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHz0bZRmei17NjDhdZVmd3W\|IH;u[UB{d2y3dHnvckBie3OjeTygTWM2OD1yLkW0{txONg>?	M2Tyb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEC1OVI5Lz5zOUSwOVUzQDxxYU6=
CCRF-CEM	MVvDfZRwfG:6aXPpeJkh[XO\|YYm=		NUHOdmoxPzJiaILz	M2j2VmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJBi[2yrdHH4[YwuemW\|aYP0ZY51KEOFUl[tR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDj[YxtfGm2ZYKtPVYh[XG3ZX;1d{BwdmVic3;seZRqd25iYYPzZZktKEmFNUC9Nk42\|ryPLh?=	NIHvZpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUSwOVUzQCd-MUm0NFU2Ojh:L3G+
Hep3B	MkDHSpVv[3Srb36gZZN{[Xl?		M{nzXFMxKG2rboO=	MXfJcohq[mm2aX;uJI9nKGi7cH;4bYEucW6mdXPl[EBJUUZzYXzwbIEheHKxdHXpckBi[2O3bYXsZZRqd25iaX6gbJVu[W5iSHXwN2Ih[2WubIOgeJJm[XSnZDDmc5IhOzBibXnud{Bu\WG\|dYLl[EBi\nSncjCxNkBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{NCCLQ{WwQVAvODV5zszNMi=>	NVP5XoF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0Olk5QDdpPkKwOFY6QDh5PD;hQi=>
Hep3B	M4nyfWZ2dmO2aX;uJIF{e2G7		NEj0dZYyPiCqcoO=	NX3Pem9{UW6qaXLpeIlwdiCxZjDofZBwgGmjLXnu[JVk\WRiVlXHSkBxem:2ZXnuJJNm[3KndHnvckBqdiCqdX3hckBJ\XB\|QjDj[YxteyCjZoTldkAyPiCqcoOgZpkhTUyLU1GsJGlEPTB;MD6wO\|nPxE1w	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR4OUi4O{c,OjB2Nkm4PFc9N2F-
HCT116	MkW3R5l1d3SxeHnjbZR6KGG\|c3H5			Mn;2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGK7IFHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxRTBwMEZOwG0v	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ4MkWzOEc,OjB4NkK1N\|Q9N2F-
NCI-H1299	MYPGeY5kfGmxbjDhd5NigQ>?		NXL6R3gxOjRiaILz	MUjJcohq[mm2aX;uJI9nKGi3bXHuJGhUWDlyIHnuJIh2dWGwIF7DTU1JOTJ7OTDj[YxteyCjc4Pld5Nm\CCjczDBb5Qh\GWpcnHkZZRqd25iYX\0[ZIhOjRiaILzJIJ6KGy3bXnu[Zgh[XO\|YYmsJGlEPTB;MD6x{txONg>?	M3HyRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEO4OVQyLz5{MUSzPFU1OTxxYU6=
LN229-Lux	NUHkOJJFTnWwY4Tpc44h[XO\|YYm=	M{fYbFIvPSC2bzCxNEB2VQ>?	NUPVfVRlOSCqch?=	MnzJTY5pcWKrdHnvckBw\iCudXPp[oVz[XOnIHHjeIl3cXS7IHnuJIh2dWGwIFzONlI6NUy3eDDj[YxteyCjdDCyMlUhfG9iMUCgeW0hcW6ldXLheIVlKG[xcjCxJIhzKHWwZHXyJI5wem2xeHnhJIZwdGyxd3XkJIJ6KDJ2IHjyd{B2dmSncjDofZBwgGmjIHL5JJJmeG:{dHXyJIdmdmViYYPzZZk>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd2NkK3OEc,OjJ5NE[yO\|Q9N2F-
MCF7	Mk\mRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Ml\5OFghcHK\|	MnzmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlM6\|ryPLh?=	MoHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEK0O\|coRjJ2NUiyOFc4RC:jPh?=
HCT116	NXPVSmpmSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NX\4PGZ4PDhiaILz	NVLvZ3VTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTBwN{lOwG0v	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6MkS3O{c,OjR3OEK0O\|c9N2F-
SKBR3	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NIDwN\|c1QCCqcoO=	MkjzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVS1LSN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NU4{PM7:TT6=	NF;TXHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4NlQ4Pyd-MkS1PFI1Pzd:L3G+
A231	Mk[xRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUm0PEBpenN?	NGnSV21CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGyN\|Eh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkG3{txONg>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4M{K2NUc,OjR5NkOyOlE9N2F-
MCF7	NEDFc3JCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFjEOWk1QCCqcoO=	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjkQvF2u	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4M{K2NUc,OjR5NkOyOlE9N2F-
HCT116	NVjHdY4ySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NX\MenR1PDhiaILz	MoLmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zLkKx{txONg>?	NF\DZYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2N\|I3OSd-MkS3OlMzPjF:L3G+
SKBR3	NHfTfXJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXS0PEBpenN?	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONQmKzJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:Oy5zMd88UU4>	NX;tWnRrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlMzPjFpPkK0O\|Y{OjZzPD;hQi=>
NCI-H1299	NIjEeYhHfW6ldHnvckBie3OjeR?=		NWXqVppSOTJiaILz	NEnCVFhT\WS3Y4Tpc44hcW5ib4j5[4VvKGOxboP1cZB1cW:wIILheIUhcW5iaIXtZY4hVkOLLVixNlk6KGOnbHzzJIlv[3WkYYTl[EBnd3JiMUKgbJJ{	NGWwWXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO4N\|kyPSd-MkWzPFM6OTV:L3G+
PC9	NHnINolEgXSxdH;4bYNqfHliYYPzZZk>		MYm3NkBpenN?	MlzKR5l1d3SxeHnjbZR6KGGpYXnud5QhUEeILXnu[JVk\WRiZYLsc5RqdmmkLYLld4l{fGGwdDDoeY1idiCSQ{mgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTBwMEJOwG0v	M33lfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OES0Olg6Lz5{Nki0OFY5QTxxYU6=
Ma1	MlXKR5l1d3SxeHnjbZR6KGG\|c3H5		MYW3NkBpenN?	NYnLRm0{S3m2b4TvfIlkcXS7IHHnZYlve3RiSFfGMYlv\HWlZXSg[ZJtd3SrbnniMZJme2m\|dHHueEBpfW2jbjDNZVEh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUCuNFHPxE1w	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh2NE[4PUc,OjZ6NES2PFk9N2F-
SKBR3	M1K4dGZ2dmO2aX;uJIF{e2G7			MV;Jcohq[mm2aX;uJI9nKEi\|cEmwJIlvKGi3bXHuJHNMSlJ\|IHPlcIx{NCCLQ{WwQVAvODJ2zszNMi=>	NG\tTnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nki0OFY5QSd-Mk[4OFQ3QDl:L3G+
HeLa	NHWwT2hHfW6ldHnvckBie3OjeR?=	NXfi[VFkOTBidV2=	M4DJVlYhcHK\|	NYjPXGNHUW6qaXLpeIlwdiCxZjDIV3A6OCCrbjDoeY1idiCKZVzhJINmdGy\|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iClaHuxJIRm\3KjZHH0bY9vKGG2IEGwJJVOKGGodHXyJFYhcHK\|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhzNkS0PUc,Ojh6MU[0OFk9N2F-
HeLa	M4\EfGZ2dmO2aX;uJIF{e2G7	NXSz[lJ1OTBidV2=	Ml;JOkBpenN?	MUDJcohq[mm2aX;uJI9nKEiVUEmwJIlvKGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJGFsfCCmZXfyZYRifGmxbjDheEAyOCC3TTDh[pRmeiB4IHjyd{BjgSCZZYP0[ZJvKGKub4SgcYV1cG:m	Ml7vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6MU[0OFkoRjJ6OEG2OFQ6RC:jPh?=
HeLa	NXjESo1nTnWwY4Tpc44h[XO\|YYm=	M3Xnb\|ExKHWP	NUHHRVdqPiCqcoO=	NULt[mJEUW6qaXLpeIlwdiCxZjDIV3A6OCCrbjDoeY1idiCKZVzhJINmdGy\|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCKU2C3NEBxem:2ZXnuJIV5eHKnc4Ppc44h[XRiMUCgeW0h[W[2ZYKgOkBpenNiYomgW4V{fGW{bjDicI91KG2ndHjv[C=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhzNkS0PUc,Ojh6MU[0OFk9N2F-
PC3	MYrGeY5kfGmxbjDhd5NigQ>?	M16xPFExKHWP	NXfGdphLPiCqcoO=	M1;BWGlvcGmkaYTpc44hd2ZiSGPQPVAhcW5iaIXtZY4hWEN\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBkcGtzIHTl[5Ji\GG2aX;uJIF1KDFyIIXNJIFnfGW{IE[gbJJ{KGK7IGfld5Rmem5iYnzveEBu\XSqb3S=	M2HnWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEG2OFQ6Lz5{OEixOlQ1QTxxYU6=
PC3	M2rC[GZ2dmO2aX;uJIF{e2G7	NGHEdVQyOCC3TR?=	NFSxcFc3KGi{cx?=	Mkf4TY5pcWKrdHnvckBw\iCKU2C5NEBqdiCqdX3hckBRSzNiY3XscJMh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJGFsfCCmZXfyZYRifGmxbjDheEAyOCC3TTDh[pRmeiB4IHjyd{BjgSCZZYP0[ZJvKGKub4SgcYV1cG:m	M2\3dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEG2OFQ6Lz5{OEixOlQ1QTxxYU6=
PC3	MV3GeY5kfGmxbjDhd5NigQ>?	MX6xNEB2VQ>?	MV:2JIhzew>?	NE[xO3hKdmirYnn0bY9vKG:oIFjTVFkxKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhUFOSN{CgdJJwfGWrbjDlfJBz\XO\|aX;uJIF1KDFyIIXNJIFnfGW{IE[gbJJ{KGK7IGfld5Rmem5iYnzveEBu\XSqb3S=	NWTUdXBKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4NVY1PDlpPkK4PFE3PDR7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	HSP90 / HSP70 ; PubMed: 28915605 Oncotarget Western blot analysis showing dose-dependent elevation of Hsp70 and HSP90 levels in AGS cells by 17-DMAG. p-Akt / Survivin / MMP2 ; PubMed: 28915605 Oncotarget Western blot analysis showing the dose-dependent reduction of the expression of HSP90 client proteins, such as p-Akt, survivin, and MMP2 by 17-DMAG. PARP / Cleaved caspase-3 / Cleaved caspase-8 / Cleaved caspase-9 / PUMA ; PubMed: 28915605 Oncotarget (C-D) 17-DMAG effects on the expression of apoptotic proteins (PARP, c-caspase 3, c-caspase-8, c-caspase-9, and PUMA) in AGS cells. Western blot analyses indicate that 17-DMAG significantly increased the expression of apoptotic proteins in AGS cells in a dose- (C) and time- (D) dependent manner (P < 0.05). p-ALK / ALK / p-Akt / Akt / p-ERK / ERK ; PubMed: 26219569 BMC Cancer Modulation of ALK signaling in parental and 17-DMAG-resistant cells. Cells were treated with the indicated concentrations of 17-DMAG or AUY922 for 6 h. The molecules of ALK-related signaling activity were detected by western blot analysis. α-Tax / α-IKKα / α-IKKβ/ α-NEMO / α-TBK1 / α-p65 / α-p50 ; PubMed: 24109220 J Virol C8166, MT-2, and MT-4 cells were treated with 17-DMAG as indicated, and cell lysates were subjected to immunoblotting with the indicated antibodies.	28915605 26219569 24109220
Growth inhibition assay	Cell proliferation ; PubMed: 28915605 Oncotarget Proliferation assay of AGS cells treated with graded concentrations of 17-DMAG for 24 h or 48 h. 17-DMAG resulted in significant dose- and time-dependent reduction of AGS cell proliferation (P < 0.05)	28915605

体内研究

17-DMAG按5 mg/kg 或 25 mg/kg处理，每周三次，显著降低 TMK-1 移植瘤生长，通过显著降低血管面积和增殖肿瘤细胞数。^[2]与抑制FAK信号一致，17-DMAG 按 25 mg/kg剂量处理小鼠，每周三次，显著抑制肿瘤生长，及ME180 和SiHa 移植瘤的转移。^[4]17-DMAG 按10 mg/kg 剂量处理TCL1-SCID移植鼠模型，处理16天，显著降低白细胞数，且延长寿命。^[5]

激酶实验：^[1]	- 合并荧光偏振（FP）为基础的竞争性结合实验: 实验使用氟化硼亚甲基二吡咯(BODIPY)标记的Geldanamycin类似物 (BODIPY-AG) 作为探针，根据探针与蛋白结合情况，测定荧光偏振。从 HeLa细胞中分离活性人类Hsp90 蛋白 (α + β 亚型)。 BODIPY-AG 溶液在FP 实验 buffer (20 mM HEPES-KOH, pH 7.3, 1.0 mM EDTA, 100 mM KCl, 5.0 mM MgCl₂, 0.01% NP-40, 0.1 mg/mL 新鲜牛γ-球蛋白 (BGG), 1.0 mM 新鲜DTT,和蛋白酶抑制剂，溶于)中新鲜制备。通过10 μL每组含 BODIPY-AG 和Hsp90的溶液，与连续稀释的 17-DMAG（在 FP 实验 buffer中新鲜制备）混合，而获得竞争性曲线。终浓度为10 nM BODIPY-AG, 40 或 60 nM Hsp90,不同浓度 17-DMAG (0.10 nM-10 μM), 和 ≤0.25% DMSO 在384孔板中混合。30^oC下温育3小时后, 在EnVision 2100多标记酶标仪上测定荧光各向异性(γEx = 485 nm, γEm = 535 nm) 。从竞争曲线中获得17-DMAG的IC50值。
细胞实验：^[5]	- 合并 Cell lines: 慢性淋巴细胞白血病(CLL) Concentrations: 溶于DMSO,终浓度为~1 μM Incubation Time: 24, 或48小时 Method: 使用不同浓度17-DMAG 处理细胞24,或48小时。为了测量毒性, 加如MTT试剂，实验板再温育24小时，然后使用分光光度法测量。通过膜联蛋白 V-异硫氰酸荧光素和碘化丙啶(PI)染色测定凋亡。 (Only for Reference)
动物实验：^[5]	- 合并 Animal Models: 移植TCL1 白血病细胞的SCID小鼠 Dosages: 10 mg/kg Administration: 腹腔注射，每周5次 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	131 mg/mL (200.54 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 1% DMSO+30% polyethylene glycol+1% Tween 80	30 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Alvespimycin (17-DMAG) HCl SDF

分子量	653.21
化学式	C₃₂H₄₈N₄O₈•HCl
CAS号	467214-21-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	NSC 707545,BMS 826476 HCl,KOS 1022

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

选择性强的HSP90抑制剂

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
活性最高的HSP90抑制剂

KW-2478 : HSP90, IC50=3.8 nM.
用于临床的HSP90抑制剂

17-AAG (Tanespimycin) : Phase III for Gastrointestinal Stromal Tumors.
最新的HSP90抑制剂

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

研究领域

产品类型

定制您的化合物库

Alvespimycin (17-DMAG) HCl

客户使用Selleck生产的Alvespimycin (17-DMAG) HCl发表文献48篇：

产品安全说明书

HSP (HSP90)抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Alvespimycin (17-DMAG) HCl SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

相关HSP (HSP90)产品